Michael D. Pak

Array ( [id] => 16359444 [patent_doc_number] => 20200316195 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-08 [patent_title] => TfR SELECTIVE BINDING COMPOUNDS AND RELATED METHODS [patent_app_type] => utility [patent_app_number] => 16/946524 [patent_app_country] => US [patent_app_date] => 2020-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29301 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 67 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16946524 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16329894 [patent_doc_number] => 20200300860 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-24 [patent_title] => FUSION PROTEINS AND METHODS THEREOF [patent_app_type] => utility [patent_app_number] => 16/899312 [patent_app_country] => US [patent_app_date] => 2020-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 56115 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16899312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17793533 [patent_doc_number] => 20220252625 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-11 [patent_title] => TREATMENT AND DIAGNOSIS OF CHRONIC INFLAMMATORY CONDITIONS IN THE LOWER URINARY TRACT [patent_app_type] => utility [patent_app_number] => 17/617204 [patent_app_country] => US [patent_app_date] => 2020-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13428 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -43 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17617204 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17760097 [patent_doc_number] => 20220233709 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-28 [patent_title] => Masked Antibody Formulations [patent_app_type] => utility [patent_app_number] => 17/614788 [patent_app_country] => US [patent_app_date] => 2020-06-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28175 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -145 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614788 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16343602 [patent_doc_number] => 20200308252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => METHOD FOR TREATING CD40-MEDIATED DISEASES [patent_app_type] => utility [patent_app_number] => 16/890486 [patent_app_country] => US [patent_app_date] => 2020-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20016 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16890486 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17720432 [patent_doc_number] => 20220213152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => ?-GLUCAN-BINDING PROTEIN, ?-GLUCAN DETECTION KIT, ARTIFICIAL DNA, AND BACTERIUM [patent_app_type] => utility [patent_app_number] => 17/616853 [patent_app_country] => US [patent_app_date] => 2020-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5265 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17616853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18642415 [patent_doc_number] => 11766468 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-09-26 [patent_title] => Method of treating prostate cancer with GnRH antagonist [patent_app_type] => utility [patent_app_number] => 16/880608 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 12 [patent_no_of_words] => 22429 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 124 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16880608 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776827 [patent_doc_number] => 20220243176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => SPECIFIC SELECTION OF IMMUNE CELLS USING VERSATILE DISPLAY SCAFFOLDS [patent_app_type] => utility [patent_app_number] => 17/614711 [patent_app_country] => US [patent_app_date] => 2020-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17471 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17614711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16400133 [patent_doc_number] => 20200340991 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-29 [patent_title] => Compositions and Methods for Detecting Autoantibodies [patent_app_type] => utility [patent_app_number] => 16/871554 [patent_app_country] => US [patent_app_date] => 2020-05-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10802 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16871554 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16236789 [patent_doc_number] => 20200254023 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-08-13 [patent_title] => CD123-Specific Chimeric Antigen Receptor Redirected T Cells and Methods of Their Use [patent_app_type] => utility [patent_app_number] => 16/859590 [patent_app_country] => US [patent_app_date] => 2020-04-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13020 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 78 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16859590 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16755342 [patent_doc_number] => 10973870 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-13 [patent_title] => Methods of treating prostate cancer with GnRH antagonist [patent_app_type] => utility [patent_app_number] => 16/851179 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 19301 [patent_no_of_claims] => 15 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16851179 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16779384 [patent_doc_number] => 20210116462 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => Methods and Compositions for the Diagnosis and Treatment of Kawasaki Disease [patent_app_type] => utility [patent_app_number] => 16/841575 [patent_app_country] => US [patent_app_date] => 2020-04-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16841575 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17334688 [patent_doc_number] => 20220001019 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-01-06 [patent_title] => RANDOM CONJUGATE MOLECULE AND METHODS OF MAKING AND USING THE SAME [patent_app_type] => utility [patent_app_number] => 16/839717 [patent_app_country] => US [patent_app_date] => 2020-04-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16839717 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16691668 [patent_doc_number] => 20210074147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/828351 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16691668 [patent_doc_number] => 20210074147 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-11 [patent_title] => PROLACTIN RECEPTOR BINDING PROTEINS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/828351 [patent_app_country] => US [patent_app_date] => 2020-03-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 69105 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16828351 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19505186 [patent_doc_number] => 12116598 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-15 [patent_title] => Thymic epithelial cells, exosomes derived therefrom, and methods of making and using same [patent_app_type] => utility [patent_app_number] => 16/823737 [patent_app_country] => US [patent_app_date] => 2020-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 15 [patent_no_of_words] => 8704 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16823737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657079 [patent_doc_number] => 20220177544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells [patent_app_type] => utility [patent_app_number] => 17/439367 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17657079 [patent_doc_number] => 20220177544 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-09 [patent_title] => Interleukin-2 receptor (IL2R) and interleukin-2 (IL2) variants for specific activation of immune effector cells [patent_app_type] => utility [patent_app_number] => 17/439367 [patent_app_country] => US [patent_app_date] => 2020-03-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 40061 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -74 [patent_words_short_claim] => 128 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17439367 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16111663 [patent_doc_number] => 20200207854 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/800458 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28464 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 132 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16800458 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16012839 [patent_doc_number] => 20200181262 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-06-11 [patent_title] => HUMANIZED AFFINITY MATURED ANTI-FcRn ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/800480 [patent_app_country] => US [patent_app_date] => 2020-02-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28460 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 151 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16800480 [rel_patent_id] =>[rel_patent_doc_number] =>)